Acumen Pharmaceuticals Q2 net loss widens, misses analyst estimates - ABOS News | RalliesAcumen Pharmaceuticals Q2 net loss widens, misses analyst estimates
A
ABOS• Outlook and analyst coverage
- Company expects topline results from ALTITUDE-AD Phase 2 study in late 2026
- Acumen targets IND filing for EBD program lead candidate in mid-2027
- Company expects cash to support operations into early 2027
- Current average analyst rating on the shares is "strong buy" with 6 "strong buy" or "buy" recommendations, no "hold" and no "sell" or "strong sell"
- Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 223.9% above its August 11 closing price of $2.47
Q2 loss widens and misses estimates
- US Alzheimer's therapeutics developer's Q2 net loss missed analyst expectations
- Q2 loss from operations also missed analyst estimates
- Q2 net loss: $32.72 million vs consensus $23.28 million from 5 analysts
- Q2 income from operations: vs consensus from 5 analysts
-$32.56 million
-$24.58 million
Q2 loss per basic share: $0.45Q2 operating expenses: $32.56 millionR&D expenses fall as trial costs decline
- R&D expenses fell year over year due to lower manufacturing and CRO costs for the ALTITUDE-AD trial
- Lower manufacturing and CRO costs for the ALTITUDE-AD clinical trial led to a decrease in R&D expenses
- Nomination of two Enhanced Brain Delivery program candidates and IND-enabling activities advanced pipeline development
